Loading clinical trials...
Loading clinical trials...
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LA...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alkermes, Inc.
NCT07565428 · Negative Symptoms of Schizophrenia
NCT07645443 · Early Onset Psychosis, First Psychotic Episode Within the Last 5 Years, and more
NCT07288333 · Schizophrenia
NCT07105098 · Schizophrenia
NCT06743711 · Severe Mental Illness, Schizophrenia Spectrum &Amp; Other Psychotic Disorders, and more
Alkermes Investigational Site
Tucson, Arizona
Alkermes Investigational Site
Costa Mesa, California
Alkermes Investigational Site
El Cajon, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions